To include your compound in the COVID-19 Resource Center, submit it here.

Xanelim anti-CD11a: Phase I/II data; Phase III

XOMA said data from an open-label, 12-week Phase I/II trial in the U.S. and Canada showed 46 of 61 (75 percent) patients given Xanelim had a??50

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE